Status: Available
Post-Trial Access to ATH434 for Patients With Multiple System Atrophy
This multicenter post-trial access program is designed to provide ATH434 orally BID to eligible patients who completed Phase 2 studies ATH434-201 or ATH434-202, and who may benefit from this treatment according to the evaluation by their treating physicians.
Trial details
Biological sex: AllType: Expanded AccessSponsor: Alterity TherapeuticsUpdated: Apr 15, 2026
Eligibility criteria
Completed Alterity protocol ATH434-201 or ATH434-202 [+1]
Discontinued prior ATH434 treatment (ATH434-201 or ATH434-202) for any reason [+1]